Scott Hecker retweeted
Want to see @IDWeek2022 of xeruborbactam head-to-head testing vs invest IV & oral beta-lactam/betaL-ase inhibs or activity vs DTR #AMR vs pathogens. TODAY: See posters 1692-3 by Olga Lomovskaya @mcastanheirajmi, & # 1736-7 by @IDPittStop Hong Nguyen, @ClancyNeil @ryankshields
Selection of QPX7831, an Orally Bioavailable Prodrug of Boronic Acid β-Lactamase Inhibitor QPX7728 pubs.acs.org/doi/10.1021/acs…
Scott Hecker retweeted
I miss #IDWeek2021 poster session discussions. Which oral beta-lactam antibiotic with QPX7728 looks most interesting vs resistant Enterobacterales? @gardp_amr @SIDPharm @CARB_X @AWG_News – at California, USA
@IDWeek2021: @mcastanheirajmi shows data on our beta-lactamase inhibitor QPX7728 delivered IV or PO restores the potency of multiple oral and IV beta-lactams vs R Enterobacteriales, including ESBL, KPC, OXA, & MBL strains. bit.ly/39RZIph
Scott Hecker retweeted
When I began my career in '80s, I practiced what is now called “antibiotic stewardship”– the right antibiotic to the right patient. But it was “patient stewardship.” We need to reform how best antibiotics are valued and reform how insurance pays for them.sandiegouniontribune.com/opi…
Scott Hecker retweeted
A scalable synthesis of β-lactamase inhibitor QPX7728 features a Ni-catalyzed boron insertion into a benzofuran followed by enantioselective cyclo-propanation with (+)-pseudoephedrine. bit.ly/3Aujz9H
Qpex Biopharma reports on an efficient process for manufacture of β-lactamase inhibitor QPX7728, featuring Ni-catalyzed boron insertion and enantioselective cyclopropanation pubs.acs.org/doi/10.1021/acs…
Scott Hecker retweeted
Our CEO @MikeMndudley and SVP Olga Lomovskaya discuss #AMR and the pressing need for new and better antimicrobials – ones that address resistance of both class-specific and general-intrinsic mechanisms.
Read more: revive.gardp.org/will-new-an…
ORAvance provides convenient oral delivery of QPX7728, our ultra-broad-spectrum beta-lactamase inhibitor that is also progressing in Phase 1 clinical trials in an IV form. businesswire.com/news/home/2…
Scott Hecker retweeted
Poster presentations (AAR-706 to 713) at #ASMicrobe on details of Qpex Biopharma’s ultra-broad-spectrum beta-lactamase inhibitor QPX7728 for IV and oral administration for #AMR on Sunday afternoon. #antimicrobials @AWG_News @SIDPharm
Scott Hecker retweeted
Wonder about a career discovering new antibiotics? Wonder why finding new classes of drugs for treatment of #AMR is hard, but how we did it? Come hear Qpex’s own Scott Hecker at #ASMicrobe Career Talk at POM Lounge and Learn at Moscone WEST (level 2) at 2:30pm Sunday.
Scott Hecker retweeted
Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections prn.to/2GRDRAG